Enlivex Therapeutics Ltd.
ENLV
$1.05
-$0.05-4.55%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | 43.09% | 56.36% | 54.42% | 42.64% | -26.51% |
| Total Depreciation and Amortization | -82.00% | -24.77% | -24.53% | -10.05% | -9.50% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -85.19% | 82.21% | -41.40% | -81.91% | 171.01% |
| Change in Net Operating Assets | -34.15% | -260.72% | 140.31% | 4.56% | -14.44% |
| Cash from Operations | 22.61% | 51.88% | 74.41% | 22.03% | -9.53% |
| Capital Expenditure | -400.00% | 68.97% | 57.89% | 73.46% | 99.73% |
| Sale of Property, Plant, and Equipment | 480.39% | -- | -98.78% | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -24.30% | -109.21% | 71.63% | 115.77% | 1,486.78% |
| Cash from Investing | -18.79% | -64.59% | 70.61% | 116.26% | 243.78% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1,146.41% | -- | -- | 14.89% | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -322.22% | -- | -89.47% | 89.47% | -- |
| Cash from Financing | -- | -- | 10,421.43% | 64.78% | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 146.85% | 35.07% | 118.88% | 103.02% | 85.16% |